+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pediatric Neuroblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851950
  • Report
  • October 2018
  • Region: Global
  • 143 pages
  • Transparency Market Research
1 of 2

Pediatric Neuroblastoma Treatment Market - Overview

This report by Transparency Market Research analyzes the global pediatric neuroblastoma treatment market for the period between 2018 and 2026. An in-depth market assessment has been made, which offers readers accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various products as well as new players planning to enter this market.

The global pediatric neuroblastoma treatment market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape by major players operating in this market along with their shares (value %) of the global pediatric neuroblastoma treatment market for 2017. The report also provides detailed company profiles of emerging market players operating in the global market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global pediatric neuroblastoma treatment market. These factors are likely to aid stakeholders establish a strong foothold in the global market. Furthermore, the overview section comprises market attractiveness analysis, global market analysis, and forecast of the global pediatric neuroblastoma treatment market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global pediatric neuroblastoma treatment market has been segmented based therapy type and distribution channel. In terms of therapy type, the global market has been classified into immunotherapy, chemotherapy, and others. Based on distribution channel, the global pediatric neuroblastoma treatment market has been categorized into hospital pharmacies and retail pharmacies & drug stores.

In terms of region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global pediatric neuroblastoma treatment market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global pediatric neuroblastoma treatment market that is expected to assist new companies establish their presence and expanding their share in the market. The report concludes with the company profile section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments.

Competitive Landscape

Major players operating in the global pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pediatric Neuroblastoma Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Epidemiology Pediatric Neuroblastoma
5.2. Pipeline Analysis
5.3. Key Unmet Needs in the Pediatric Neuroblastoma Treatment Market
5.4. Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis in Neuroblastoma
5.5. Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases
5.6. Rate of Utilization of MIBG-131

6. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2016-2026
6.3.1. Immunotherapy
6.3.2. Chemotherapy
6.3.3. Others
6.4. Market Attractiveness, by Therapy Type

7. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2016-2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.4. Market Attractiveness, by Distribution Channel

8. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Rest of the World
8.3. Market Attractiveness, by Region

9. North America Pediatric Neuroblastoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy Type, 2016-2026
9.2.1. Immunotherapy
9.2.2. Chemotherapy
9.2.3. Others
9.3. Market Value Forecast, by Distribution Channel, 2016-2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.4. Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Pediatric Neuroblastoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2016-2026
10.2.1. Immunotherapy
10.2.2. Chemotherapy
10.2.3. Others
10.3. Market Value Forecast, by Distribution Channel, 2016-2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies & Drug Stores
10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Rest of the World Pediatric Neuroblastoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2016-2026
11.2.1. Immunotherapy
11.2.2. Chemotherapy
11.2.3. Others
11.3. Market Value Forecast, by Distribution Channel, 2016-2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies & Drug Stores
11.4. Market Attractiveness Analysis
11.4.1. By Therapy Type
11.4.2. By Distribution Channel

12. Company Profiles
12.1. United Therapeutics Corporation
12.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2. Product Portfolio
12.1.3. SWOT Analysis
12.1.4. Financial Overview
12.1.5. Strategic Overview
12.2. APEIRON Biologics AG
12.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2. Product Portfolio
12.2.3. SWOT Analysis
12.2.4. Financial Overview
12.2.5. Strategic Overview
12.3. Baxter
12.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.2. Product Portfolio
12.3.3. SWOT Analysis
12.3.4. Financial Overview
12.3.5. Strategic Overview
12.4. Cellectar Biosciences, Inc.
12.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.4.2. Product Portfolio
12.4.3. SWOT Analysis
12.4.4. Financial Overview
12.4.5. Strategic Overview
12.5. Pfizer, Inc.
12.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.5.2. Product Portfolio
12.5.3. SWOT Analysis
12.5.4. Financial Overview
12.5.5. Strategic Overview
12.6. MacroGenics, Inc.
12.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.6.2. Product Portfolio
12.6.3. SWOT Analysis
12.6.4. Financial Overview
12.6.5. Strategic Overview
12.7. Bayer AG
12.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.7.2. Product Portfolio
12.7.3. SWOT Analysis
12.7.4. Financial Overview
12.7.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll